Questioning How to Define the "Ultra-High-Risk" Subgroup of Neuroblastoma Patients.

Demir, A B; Aktas, S; Altun, Z; Ercetin, P; Aktas, T C; Olgun, N

Demir, A B; Aktas, S; Altun, Z; Ercetin, P; Aktas, T C; Olgun, N.

Afiliação

Demir AB; Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.
Aktas S; Department of Basic Medical Sciences, Faculty of Medicine, Izmir University of Economics, Izmir, Turkey.
Altun Z; Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.
Ercetin P; Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.
Aktas TC; Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.
Olgun N; Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.

Folia Biol (Praha) ; 67(1): 1-9, 2021.

Article em En | MEDLINE | ID: mdl-34273261

Assuntos

Neuroblastoma; Quinase do Linfoma Anaplásico/genética; Estudos Transversais; Humanos; Imuno-Histoquímica; Neuroblastoma/genética; Estudos Retrospectivos

Buscar no Google

Imprimir

XML

PubMed Links